openPR Logo
Press release

Exclusive Forecast Study: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026

11-27-2018 07:43 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Type 2 Diabetes

Global Type 2 Diabetes Market

Global Type 2 Diabetes Market

ResearchMoz presents professional and in-depth study of "PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026". This research assessment offers a clear insight about the influential factors that are expected to transform the global market in the near future.

Summary

While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1350131

Despite the large number of marketed therapies, the T2D market is still experiencing large unmet needs and therefore has a significant growth opportunity for new patent-protected products. Metformin (dimethylbiguanide) will remain the first-line therapy overall for T2D due to physicians familiarity with it and the availability of long-term data, but the usage of sulfonylureas (SUs), another front-line therapy, continues to be replaced by novel therapies with improved side-effect profiles. The battle for second- or third-line therapy will involve DPP-4Is, GLP-1RAs, SGLT-Is, and other upcoming novel therapies. Of all the currently marketed classes, GLP-1RAs and SGLT-Is will experience the fastest growth due to their beneficial CV effects, weight-loss effects, and increasing ease of use.

Scope

- Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/pharmapoint-type-2-diabetes-global-drug-forecast-and-market-analysis-to-2026-report.html/toc

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global T2D therapeutics market from 2016-2026.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ https://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Exclusive Forecast Study: PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026 here

News-ID: 1400665 • Views:

More Releases from Type 2 Diabetes

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate P …
Albany, NY, Feb 27, 2017: Type 2 diabetes mellitus (T2DM) is a chronic, progressive and serious metabolic disorder characterized by hyperglycemia (high blood glucose levels) and associated with numerous complications and co-morbidities, including cardiovascular, renal and neurodegenerative diseases. Global prevalence of the disease has risen rapidly in the past several decades, primarily as a result of rising obesity, a major risk factor for T2DM. This has resulted in a large and
Type 2 Diabetes Mellitus Therapeutics In South-East Asia Markets To 2022 - Incre …
Worldwide Market studies the current scenario as well as future market potential of "Type 2 Diabetes Mellitus Therapeutics In South-East Asia Markets To 2022 - Increasing Usage Of Newer Therapies And Expanding Treatment Population To Encourage Robust Growth" Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. This

More Releases for T2D

Hemochromatosis-Global Drug Forecast and Market Analysis to 2026
Summary:                                      ReportsWeb.com published “Hemochromatosis-Global Drug Forecast and Market Analysis to 2026” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, Publisher expects this market to undergo substantial growth between 2016 and 2026, doubling over the
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026
"The Report PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Type 2 Diabetes Market While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over
Epidemiology Market Analysis and Forecast to 2026-Identify the Percentage of T2D …
Market Analysis Research Report on “EpiCast Report: Type 2 Diabetes-Epidemiology Forecast to 2026” has been added to orbis research database. Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body’s inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90-95% of all diabetes cases around the world, while
EpiCast Report: Type 2 Diabetes - Epidemiology Pipeline Insight and Therapeutic …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026”. Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the bodys inability to make use of available insulin along with relative insulin deficiency. Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1287567 T2D
EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026
EpiCast Report: Type 2 Diabetes - Epidemiology Forecast to 2026 View Full Report : https://www.marketresearchreports.biz/reports/1287567/epicast-report-type-2-diabetes-epidemiology-forecast-to-2026-market-research-reports.pdf Summary Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the bodys inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes and gestational diabetes
Type 2 Diabetes - Epidemiology Forecast To 2025
Summary Type 2 diabetes (T2D), formerly known as non-insulin dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the bodys inability to make use of available insulin along with relative insulin deficiency. T2D constitutes approximately 90% of all diabetes cases around the world; type 1 diabetes (T1D) and gestational diabetes make up the remaining 10% of the cases. Risk factors for T2D are